APTOSE BIOSCIENCES (APTO) Covered Calls

You can sell covered calls on APTOSE BIOSCIENCES to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for APTO (prices last updated Thu 4:16 PM ET):

APTOSE BIOSCIENCES (APTO) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.28 -0.04 2.00 2.48 59K - 0.1B
Covered Calls For APTOSE BIOSCIENCES (APTO)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Oct 19 2.5 0.00 2.48 0.0% 0.0%
Nov 16 2.5 0.00 2.48 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company's clinical programs is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in late preclinical development stage for the treatment of patients with relapsed/refractory acute myeloid leukemia and having B-cell malignancies. The company also has an agreement with Ohm Oncology for development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada